Camurus AB (publ)

Camurus AB (publ), founded in 1991 and headquartered in Lund, Sweden, is a pharmaceutical firm focused on the creation and commercialization of medications for severe and persistent illnesses. Its market reach extends across Europe, Australia, the United States, Japan, and other international territories. The company's current product offerings include Buvidal, an injectable buprenorphine formulation used to manage opioid dependence, and Brixadi, also prescribed for opioid use disorder. Additionally, it markets episil oral liquid, a medical device designed to treat painful and inflammatory conditions affecting the oral cavity. Camurus maintains an active development pipeline featuring several investigational therapies. These include CAM2038 for chronic pain, and CAM2029, which is progressing through Phase III clinical trials for acromegaly and neuroendocrine tumors, alongside Phase II studies for polycystic liver diseases. CAM2043 is currently in Phase I trials for pulmonary arterial hypertension and Phase II for Raynaud's phenomenon. Further programs encompass CAM2032 (Phase II for prostate cancer), CAM4072 (Phase III for genetic obesity disorders), CAM4071 (Phase I for an endocrine disorder), CAM2047 (Phase I for chemotherapy-induced nausea and vomiting), and CAM2048 (Phase I for postoperative pain).